Skip Ribbon Commands
Skip to main content


GECCO has conducted genome-wide association tests in a population-based setting for both overall survival and colorectal cancer survival, and continues to investigate how genetic variations may affect outcomes.
Long time GECCO collaborators, Dr. Polly Newcomb and Dr. Andrew Chan are co-leading the “Molecular Correlates of Outcomes in Clinical Trials” study with the goal of finding correlations between a person’s chance of surviving colorectal cancer and their germline genetic variations. Drs. Chan and Newcomb are coordinating this study with Massachusetts General Hospital and the Mayo Clinic to genotype DNA samples from clinical trials. Genotyping is occurring at the Center for Inherited Disease Research center. 
The "Molecular Correlates of Outcomes in Clinical Trials" project aims to identify genetic loci associated with survival outcomes among patients with stage II-III colon cancer, and to identify the genetic association with treatment-associated serious adverse events among patients with stage II-III colon cancer. The study also examines the impact of adding information on germline genetic loci to existing prognostic models for stage II-III colon cancer, which are currently based on patient characteristics and clinical factors, such as age, sex, tumor location, tumor stage, and histological grade. 

Related Information

Estrogen receptor ß genes assocaited with coloreactal cancer mortality (January 20, 2013)


Web Part Error: Access denied. You do not have permission to perform this action or access this resource. Correlation ID: 1a9ca3a0-7601-b0d2-8485-200922ebd73b.